Aztreonam avibactam clinical trials have evaluated the combination in serious Gram-negative bacterial infections, including complicated intra-abdominal infections, hospital-acquired or ventilator-associated pneumonia, and infections caused by metallo-beta-lactamase (MBL)-producing organisms. Clinical studies such as REVISIT, ASSEMBLE and REJUVENATE provide evidence about efficacy, microbiological response and safety, while also showing important limitations in the current evidence base.

Aztreonam-avibactam combines the monobactam antibiotic aztreonam with the beta-lactamase inhibitor avibactam. The combination has attracted clinical interest because of its activity against certain difficult-to-treat Gram-negative pathogens, particularly organisms carrying metallo-beta-lactamases.

However, clinical trial evidence needs to be interpreted carefully. Different studies enrolled different patient populations, used different comparators and had different sample sizes. In particular, evidence for MBL-producing infections comes from relatively small clinical populations.

This article reviews the major aztreonam avibactam clinical trials, their outcomes and the limitations that should be considered when interpreting the evidence.

Aztreonam Avibactam Clinical Trials at a Glance

Several studies have contributed to the clinical development of aztreonam-avibactam.

The major studies include:

Study	Phase	Population	Main focus
REJUVENATE	Phase 2a	34 patients with cIAI	Early efficacy, PK and safety
REVISIT	Phase 3	422 patients	cIAI and HAP/VAP
ASSEMBLE	Phase 3	15 randomized patients	MBL-producing Gram-negative infections

These studies should not be interpreted as though they were interchangeable.

REJUVENATE was an earlier-stage study with a relatively small population.

REVISIT provided larger Phase 3 evidence across complicated intra-abdominal infections and hospital-acquired or ventilator-associated pneumonia.

ASSEMBLE specifically addressed infections involving MBL-producing Gram-negative organisms but had a very small randomized population.

Together, the studies provide clinical evidence for aztreonam-avibactam while also demonstrating why further real-world and larger-population evidence remains valuable.

REVISIT Phase 3 Trial of Aztreonam Avibactam

The REVISIT study is one of the most important aztreonam avibactam Phase 3 trials.

It evaluated aztreonam-avibactam in adults with serious Gram-negative bacterial infections, including:

Complicated intra-abdominal infections (cIAI)
Hospital-acquired pneumonia (HAP)
Ventilator-associated pneumonia (VAP)

The study included 422 patients.

Of these:

282 patients received aztreonam-avibactam
140 patients received the comparator regimen of meropenem ± colistin

The study therefore provided substantially more clinical information than the smaller early-stage studies.

REVISIT Clinical Cure Results

The reported overall clinical cure rate was:

Aztreonam-avibactam: 68.4%
Comparator: 65.7%

For complicated intra-abdominal infections:

Aztreonam-avibactam: 76.4%
Comparator: 74.0%

For HAP/VAP:

Aztreonam-avibactam: 45.9%
Comparator: 41.7%

These results provide clinical evidence supporting the activity of the combination in the studied populations.

However, the results should be interpreted according to the study’s design and statistical framework.

REVISIT Was Not a Simple “Proof of Superiority”

It is important not to describe the REVISIT findings as though the trial simply demonstrated that aztreonam-avibactam was superior to the comparator.

The reported outcomes were descriptive, and the study should be interpreted within its predefined methodology.

Therefore, a more accurate statement is that REVISIT provided Phase 3 clinical evidence of efficacy for aztreonam-avibactam in the studied infection populations.

REVISIT and 28-Day Mortality

The reported 28-day mortality was:

4% with aztreonam-avibactam
7% with the comparator

Mortality is an important clinical outcome in serious bacterial infections.

However, mortality results should not be interpreted independently of:

Baseline disease severity
Infection type
Patient characteristics
Comparator treatment
Sample size
Study design

A difference in observed mortality between treatment groups does not automatically establish that the treatment caused the difference.

Safety Findings from REVISIT

The REVISIT study also provided important safety information.

The available evidence indicated that aztreonam-avibactam was generally tolerated in the study population.

No treatment-related serious adverse events were reported in the aztreonam-avibactam group.

This finding should be interpreted in the context of the specific clinical trial population.

It does not mean that serious adverse events cannot occur during treatment.

For a detailed discussion of adverse reactions and safety warnings, see the dedicated Aztreonam Avibactam Side Effects guide.

ASSEMBLE Phase 3 MBL Trial

The ASSEMBLE study is particularly important when discussing the clinical evidence for aztreonam-avibactam against metallo-beta-lactamase-producing Gram-negative bacteria.

MBL-producing organisms can present major treatment challenges because metallo-beta-lactamases can hydrolyze many beta-lactam antibiotics.

The ASSEMBLE study therefore focused on a population that is highly relevant to the scientific rationale behind aztreonam-avibactam.

ASSEMBLE Study Population

The randomized population was very small.

A total of 15 patients were randomized:

12 patients to aztreonam-avibactam
3 patients to best available therapy (BAT)

This small sample size is one of the most important factors when interpreting ASSEMBLE.

ASSEMBLE Clinical Cure Results

Clinical cure was reported in:

5 of 12 patients (41.7%) receiving aztreonam-avibactam
0 of 3 patients receiving BAT

Microbiological response was reported in:

6 of 12 patients (50%) receiving aztreonam-avibactam
0 of 3 patients receiving BAT

These findings provide supportive clinical evidence in MBL-producing infections.

However, the very small number of randomized patients means that these results should be considered exploratory rather than definitive.

Why the ASSEMBLE Sample Size Matters

A study involving only 15 randomized patients cannot provide the same level of statistical certainty as a much larger Phase 3 trial.

The results can be influenced substantially by individual patient characteristics and outcomes.

Therefore, it would be inappropriate to use the ASSEMBLE results alone to estimate the overall effectiveness of aztreonam-avibactam against all MBL-producing infections.

The study is better understood as an important clinical evidence source supporting further evaluation of the combination in this difficult-to-treat population.

ASSEMBLE and Mortality

Mortality was reported in:

1 of 12 patients receiving aztreonam-avibactam
1 of 3 patients receiving BAT

Because of the extremely small comparator group, these numbers should not be used to draw broad conclusions about comparative mortality.

This is a good example of why clinical trial results need to be interpreted together with sample size and study design.

REJUVENATE Phase 2a Study

REJUVENATE represents an earlier stage of clinical development for aztreonam-avibactam.

The study included 34 patients with complicated intra-abdominal infections.

Its objectives included evaluating aspects such as:

Pharmacokinetics
Dosing
Clinical response
Safety
Microbiological outcomes

Because it was a smaller Phase 2a study, it provides useful early clinical evidence but should not be treated as equivalent to larger Phase 3 evidence.

REJUVENATE Clinical Outcomes

The reported clinical cure rate was:

58.8%

The microbiological modified-intent-to-treat cure rate was:

60.9%

These findings provided early evidence that aztreonam-avibactam could produce clinical and microbiological responses in the studied population.

However, the relatively small sample size limits the conclusions that can be drawn from this study alone.

REJUVENATE Safety Findings

Reported adverse events included:

Hepatic enzyme increases: 26.5%
Diarrhea: 14.7%

The study did not identify new safety concerns during the evaluation.

However, these percentages should not be used as current estimates of the overall adverse-effect frequency of aztreonam-avibactam.

Later-stage clinical trials and current regulatory product information provide a broader safety context.

What Do Aztreonam Avibactam Clinical Trials Show Overall?

When the major studies are considered together, several themes emerge.

1. Clinical evidence exists across different infection settings

The clinical development program has evaluated aztreonam-avibactam in different serious Gram-negative infections.

REVISIT provided evidence in cIAI and HAP/VAP, while ASSEMBLE specifically examined MBL-producing infections.

2. Phase 3 evidence is stronger than early Phase 2 evidence

REJUVENATE provided early clinical and pharmacokinetic information.

REVISIT provided a much larger Phase 3 dataset.

ASSEMBLE provided clinically relevant evidence in MBL-producing infections but involved a very small randomized population.

3. MBL clinical evidence remains relatively limited

The scientific rationale for aztreonam-avibactam includes its potential role against certain MBL-producing organisms.

However, the number of patients studied clinically for these infections remains much smaller than the broader Phase 3 populations.

4. In-vitro activity is not the same as clinical cure

Laboratory susceptibility results can help identify whether an organism is susceptible to an antimicrobial combination.

But in-vitro susceptibility does not automatically guarantee clinical cure.

Clinical outcomes depend on multiple factors, including:

Site of infection
Disease severity
Drug exposure
Source control
Patient characteristics
Organism susceptibility
Appropriate dosing

Aztreonam Avibactam Clinical Evidence in MBL and NDM Infections

One of the major areas of interest in the clinical development of aztreonam-avibactam is treatment of infections caused by MBL-producing organisms.

Important MBL families include:

These enzymes can create resistance to multiple beta-lactam antibiotics.

Aztreonam is structurally different from many other beta-lactams and is not hydrolyzed by MBLs. However, other beta-lactamases produced by the same organism can inactivate aztreonam.

Avibactam can inhibit several of those accompanying serine beta-lactamases.

This provides the biological rationale for combining the two agents.

However, this mechanistic rationale should not be confused with clinical outcome evidence.

The ASSEMBLE study is particularly relevant because it evaluated patients with MBL-producing Gram-negative infections, but the small sample size means that broader conclusions require caution.

For a detailed explanation of the mechanism and MBL resistance, see our MBL resistance and aztreonam-avibactam resource.

FDA and European Regulatory Evidence

Regulatory approvals provide another important way to understand the clinical evidence.

The approved indications are not identical across all jurisdictions.

U.S. Regulatory Context

Current U.S. approval information includes the use of EMBLAVEO in adults with complicated intra-abdominal infections caused by susceptible Gram-negative organisms when there are limited or no alternative treatment options, in combination with metronidazole.

The U.S. regulatory framework therefore needs to be distinguished from broader investigational use or evidence generated in other infection types.

Clinical trial evidence from HAP/VAP or other populations should not automatically be interpreted as meaning that every indication has identical regulatory status in the United States.

European Regulatory Context

European regulatory information provides a broader indication framework.

The European product information includes indications involving:

Complicated intra-abdominal infections
Hospital-acquired pneumonia
Ventilator-associated pneumonia
Complicated urinary tract infections, including pyelonephritis
Certain infections caused by aerobic Gram-negative organisms in patients with limited treatment options

The exact approved wording and treatment conditions should always be checked against the current European product information.

This difference illustrates why clinical trial evidence and regulatory approval are related but not identical concepts.

Limitations of Current Aztreonam Avibactam Clinical Evidence

Understanding the limitations is just as important as understanding the reported outcomes.

Small MBL Clinical Populations

The ASSEMBLE study provides valuable clinical evidence in MBL-producing infections, but the randomized population was only 15 patients.

This limits the statistical certainty of the findings.

Different Infection Populations

The major trials evaluated different infection settings.

For example:

REVISIT included cIAI and HAP/VAP
ASSEMBLE focused on MBL-producing infections
REJUVENATE evaluated cIAI

Results from one infection population should not automatically be generalized to another.

Different Comparators

The studies also used different comparator approaches.

REVISIT compared aztreonam-avibactam with meropenem ± colistin, while ASSEMBLE used best available therapy.

Because comparator regimens differ, direct numerical comparison between studies can be misleading.

Limited Real-World Evidence

Clinical trials provide controlled evidence, but routine clinical practice can involve more diverse patient populations.

Important areas where additional real-world evidence can be useful include:

Critically ill patients
Patients with multiple comorbidities
Complex resistance patterns
Changing renal function
Less common infection sites
Larger MBL-producing populations

Limited Pediatric and Pregnancy Evidence

Clinical evidence in children remains limited, and pregnancy data for the combination are also limited.

These populations should therefore not be assumed to have the same evidence base as the adult clinical-trial populations.

Clinical Trials vs Current Prescribing Information

An important distinction is the difference between what was studied in clinical trials and what is currently approved for use.

Clinical trials may evaluate:

Different infection types
Different patient populations
Investigational dosing strategies
Different comparator regimens
Different endpoints

The current prescribing information reflects the regulatory assessment of the available evidence and defines approved use for the relevant jurisdiction.

Therefore, historical trial dosing should not automatically be presented as the current approved regimen.

For current dosing information, see our Aztreonam Avibactam Dosage and Administration guide.

Frequently Asked Questions About Aztreonam Avibactam Clinical Trials

What are the main aztreonam-avibactam clinical trials?

The major studies include the REJUVENATE Phase 2a study, REVISIT Phase 3 study and ASSEMBLE Phase 3 study.

What did the REVISIT trial show?

REVISIT reported an overall clinical cure rate of 68.4% with aztreonam-avibactam compared with 65.7% with the comparator. The study included patients with cIAI and HAP/VAP.

What was the ASSEMBLE trial?

ASSEMBLE was a Phase 3 study focused on serious infections caused by MBL-producing Gram-negative bacteria. Only 15 patients were randomized, making the findings supportive but limited.

What was the clinical cure rate in ASSEMBLE?

Clinical cure occurred in 5 of 12 patients (41.7%) receiving aztreonam-avibactam compared with 0 of 3 patients receiving best available therapy.

Why is ASSEMBLE evidence considered limited?

The randomized sample was extremely small. With only 15 patients, the study cannot provide the same level of certainty as a large comparative Phase 3 trial.

What did REJUVENATE study?

REJUVENATE was a Phase 2a study involving 34 patients with complicated intra-abdominal infections. It evaluated early clinical, pharmacokinetic and safety outcomes.

Does clinical trial evidence prove aztreonam-avibactam works against every MBL-producing organism?

No. Clinical evidence remains limited for some resistant organisms and MBL populations. In-vitro activity should not automatically be equated with clinical cure.

Are aztreonam-avibactam clinical trials the same as regulatory approval?

No. Clinical studies provide evidence that regulators assess when making approval decisions. The approved indication and conditions of use can differ between jurisdictions.

Is aztreonam-avibactam approved for the same infections everywhere?

No. Regulatory indications differ between the United States and Europe. The current local product information should be consulted.

Are more studies needed?

Additional clinical and real-world evidence can help clarify outcomes in larger MBL populations, diverse patient groups and routine clinical practice.

Conclusion

The available aztreonam avibactam clinical trials provide evidence across several important clinical settings.

The REVISIT Phase 3 study provided the largest clinical dataset among the major trials discussed here, evaluating cIAI and HAP/VAP. The ASSEMBLE Phase 3 study specifically addressed MBL-producing Gram-negative infections but involved only 15 randomized patients, limiting the certainty of its findings. The earlier REJUVENATE Phase 2a study provided preliminary clinical, pharmacokinetic and safety evidence in complicated intra-abdominal infections.

Overall, the clinical evidence supports continued clinical interest in aztreonam-avibactam, particularly for difficult-to-treat Gram-negative infections. At the same time, the evidence should be interpreted according to study design, population, comparator and sample size.

Most importantly, clinical trial results, laboratory susceptibility, and regulatory approval are not interchangeable concepts. Each provides different information about the role of aztreonam-avibactam.

Medical Disclaimer: This article is intended for educational and informational purposes only. It does not replace current prescribing information, clinical guidelines or advice from a qualified healthcare professional. Regulatory indications and clinical evidence may differ by country and product.